Northwestern Mutual Wealth Management Co. Has $21.53 Million Stake in Stryker Corporation $SYK

Northwestern Mutual Wealth Management Co. raised its position in Stryker Corporation (NYSE:SYK) by 3.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,420 shares of the medical technology company’s stock after acquiring an additional 1,564 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Stryker were worth $21,530,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Clarkston Capital Partners LLC lifted its stake in Stryker by 14.0% in the 2nd quarter. Clarkston Capital Partners LLC now owns 4,072 shares of the medical technology company’s stock valued at $1,611,000 after purchasing an additional 500 shares during the last quarter. Groupama Asset Managment raised its stake in Stryker by 203.1% in the second quarter. Groupama Asset Managment now owns 5,593 shares of the medical technology company’s stock valued at $2,201,000 after buying an additional 3,748 shares during the period. Johnson Financial Group Inc. lifted its position in shares of Stryker by 26.1% in the second quarter. Johnson Financial Group Inc. now owns 706 shares of the medical technology company’s stock valued at $280,000 after buying an additional 146 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Stryker during the 2nd quarter worth approximately $28,000. Finally, Baltimore Washington Financial Advisors Inc. increased its holdings in shares of Stryker by 6.6% during the 2nd quarter. Baltimore Washington Financial Advisors Inc. now owns 74,261 shares of the medical technology company’s stock worth $29,380,000 after acquiring an additional 4,602 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. Company insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.3%

SYK stock opened at $371.29 on Monday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a market capitalization of $141.99 billion, a PE ratio of 49.18, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company’s 50-day simple moving average is $368.90 and its 200 day simple moving average is $380.22. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the company earned $2.87 EPS. The business’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective on the stock. Truist Financial raised their target price on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday, November 14th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Wells Fargo & Company increased their price target on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.